Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

- - - (517)

Income before income

taxes 363 691 23 (17) 1,060

Income tax expense 72 91 2 (5) 160

Net income $291 $600 $21 $(12) $900

Preferred stock

dividends 38 - - - 38

Net income available to

common shareholders $253 $600 $21 $(12) $862

Diluted earnings per

common share $0.15 $0.53

Average common shares

outstanding-diluted 1,637 1,637

SCHERING-PLOUGH CORPORATION

Reconciliation from Reported Net Income Available to Common Shareholders and Reported Diluted Earnings Per Common Share to As Reconciled Amounts for Net Income

Available to Common Shareholders and Diluted Earnings per Common Share

(Amounts in Millions, except per share figures)

Three months ended March 31, 2007

(unaudited)

Purchase Acquisition- Other

As Accounting Related Specified As

Reported Adjustments Items Items Reconciled

Net sales $2,975 $ - $ - $ - $2,975

Cost of sales 937 - - - 937

Selling, general

and administrative 1,213 - - - 1,213

Research and development 707 - - (96) 611

Other income, net (48) - 3 - (45)

Special and acquisition-

related charges 1 - (1) - -

Equity income
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... USA (PRWEB) March 29, 2015 A ... the United States and plenary talks by four leading ... SPIE Optics + Optoelectronics next month in Prague, ... presentations in 17 conferences alongside a two-day exhibition. Sponsored ... photonics , the event will run 13-16 April in ...
(Date:3/30/2015)... , March 30, 2015  Naldemedine, an ... development by Shionogi & Co., Ltd., met its ... study (COMPOSE I) for the treatment of opioid-induced ... pain receiving opioid therapy. Study results showed that ... significantly improved the frequency of spontaneous bowel movement ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015 /PRNewswire/ ... 4901) ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: ... a leading developer and manufacturer of fully functioning human ... that the two companies have entered into a definitive ... tender offer to be followed by a second step ...
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® ... in small cell cervical cancer (SCCC) that ... Intelligence®, the company,s panomic, comprehensive tumor profiling ... which may explain sensitivities and resistance to ... of certain biomarkers may guide treatment strategies ...
Breaking Biology Technology:Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3
... (Nasdaq:,PPDI) today announced the appointment of Jose Luis ... lead the company,s delivery,of drug development services in ... City, Dr. Viramontes will provide overall management of ... brings a solid understanding of the pharmaceutical,industry in ...
... 27 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ) ... Markets Focus on Healthcare Conference on,Wednesday, December 5, 2007 ... in New York City., To access the live ... website at http://www.nastech.com approximately 15 minutes prior,to ...
... Innovations to Accelerate Workflow, CHICAGO, Nov. ... introduces the MAMMOMAT(R) Novation S, a new,digital ... for,screenings, at the 93rd Scientific Assembly and ... America (RSNA) from Nov. 25 to 30 ...
Cached Biology Technology:Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean 2Viramontes to Lead PPD Clinical Operations in Mexico, Central America and the Caribbean 3Siemens Unveils New Digital Mammography System for Optimized Screening 2
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... April 22, 2012) Researchers at Columbia University Medical ... the retention and release of the brain,s stem cells. ... neurologic development and could eventually lead to regenerative therapies ... collaborative effort of the laboratories of Drs. Anna Lasorella ...
... reductions in salt content and taxation on products containing salt ... each year from cardiovascular disease (CVD) by 2-3 per cent ... World Congress of Cardiology are the first findings from a ... year. The study set out to assess ...
... the Florida campus of The Scripps Research Institute has been ... Health to develop a range of new tests that could ... degenerative disorders of advancing age. Shuji Kishi, an assistant ... three-year study. The new tests will focus on diseases ...
Cached Biology News:'Housekeeping' mechanism for brain stem cells discovered 2'Housekeeping' mechanism for brain stem cells discovered 3Tax on salt could reduce cardiovascular disease deaths by 3 percent 2Researcher awarded $1 million for stress-associated disease and aging research 2
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... The Columbus is a flexible, fully automated microplate ... addition to its fully automated microplate strip washing ... performance and ease of operation. ... Columbus include manifolds of 8, 12 or 16 ...
... The Model 1575 immunowash microplate washer 100-240 ... that have flat-, U-, or V-bottom wells. ... horizontal and vertical needle positions to an ... crosswise aspiration, and overflow washing. It can ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
Biology Products: